Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (MARINA-OLE)
NCT05479981Phase 2Completed
- Sponsor
- Avidity Biosciences
- Start
- Aug 2022
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Conjugated siRNA, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of delpacibart etedesiran in myotonic dystrophy type 1 (DM1) (2 arms), sponsored by Avidity Biosciences. Primary endpoint: Number and severity of treatment-emergent adverse events. Started Aug 2022; status: completed.
02
Drugs
delpacibart etedesiran
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT05479981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479981.